BioMarin Pharmaceutical Inc.
BMRN
$52.88
$0.300.57%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -12.39% | 12.68% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -12.39% | 12.68% | |||
| Cost of Revenue | 7.13% | -36.51% | |||
| Gross Profit | -25.35% | 132.00% | |||
| SG&A Expenses | -22.88% | 20.77% | |||
| Depreciation & Amortization | -7.49% | -0.02% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -7.33% | -17.61% | |||
| Operating Income | -29.85% | 521.15% | |||
| Income Before Tax | 620.03% | -3.15% | |||
| Income Tax Expenses | 83.71% | 339.37% | |||
| Earnings from Continuing Operations | 326.58% | -51.49% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 326.58% | -51.49% | |||
| EBIT | -29.85% | 521.15% | |||
| EBITDA | -26.38% | 843.42% | |||
| EPS Basic | 326.25% | -51.34% | |||
| Normalized Basic EPS | -30.27% | 912.25% | |||
| EPS Diluted | 320.35% | -51.34% | |||
| Normalized Diluted EPS | -32.09% | 912.25% | |||
| Average Basic Shares Outstanding | 0.14% | 0.10% | |||
| Average Diluted Shares Outstanding | 2.83% | 0.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||